Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Pegvisomant

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Somavert

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Somavert

    Pegvisomant

    arrow
    STLE Annual Meeting
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2019 Revenue in Millions : 264

    2018 Revenue in Millions : 267

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 277

    2019 Revenue in Millions : 264

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 277

    2020 Revenue in Millions : 277

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2022 Revenue in Millions : 268

    2021 Revenue in Millions : 277

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Endocrinology

    Currency : USD

    2023 Revenue in Millions : 267

    2022 Revenue in Millions : 268

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2015 Revenue in Millions : 229

    2014 Revenue in Millions : 218

    Growth (%) : -5%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2014 Revenue in Millions : 5.50%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2016 Revenue in Millions : 232

    2015 Revenue in Millions : 218

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer Inc.

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2017 Revenue in Millions : 254

    2016 Revenue in Millions : 233

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Somavert

    Pegvisomant

    arrow
    American Thoracic Society
    Not Confirmed

    Brand Name : Somavert

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed

    Pfizer

    Pegvisomant

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2018 Revenue in Millions : 267

    2017 Revenue in Millions : 254

    Growth (%) : 5%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF